



# InCapSolution

**Dr.-Ing. Viktor Maurer**



# INDEX

1	Start page	9	Presentation - Start
2	Index	10	Presentation - Market Size
3	Page components - 1 (Logos, Typography)	11	Presentation - Product & Business Model
4	Page components - 2 (Colors)	12	Presentation - Cooperations
5	Page components - 3 (Shapes)	13	Presentation - Traction
6	Page template - gradient	14	Presentation - Traction
7	Page template - dark mode	15	
8	Page template - light mode	16	



# PRESENTATION COMPONENTS – 1

## LOGOS



## TYPOGRAPHY

01.

LOREM IPSUM

*for local application and suppression of the short-term rejection*

I'm a dummy text  
and amongst the  
fanciest of all texts!

text dummy

27.7 M

TITLE – 45PX

INDEX – 35PX

SUB-TITLE – 32PX

SUB-INDEX – 30PX


PARAGRAPH M – 22PX

PARAGRAPH S – 19PX




# PRESENTATION COMPONENTS – 2


## COLORS




#172554




#737373




#BBCBCD




#FFFFFF




#1C4ED8




#D9D9D9




#C2A707




#FCDC57



#000000



#DDE9F2










#22C55D



# PRESENTATION COMPONENTS – 3

SHAPES





# PAGE TEMPLATE – GRADIENT



# PAGE TEMPALTE – DARK MODE



# PAGE TEMPLATE – LIGHT MODE





01.

## NEW IMMUNOSUPPRESSIVE DRUG

*for local application and suppression of the short-term rejection*

02.

## PREVENTION OF SIDE EFFECTS

*leads to an improved therapy efficiency and increased survival rate*

03.

## INNOVATIVE TREATMENT CONCEPT

*will be applied to other medical indications such as chronic wounds*

**Increasing treatment  
success and clinical  
relevance of skin  
allotransplants!**



# MARKET SIZE

27.7 M

Patients with burn injuries and chronic wounds  
annually and worldwide

3.2 M

Patients with complex wounds  
annually in Europe


1.5 K

Allogeneic skin grafts for burn patients  
annually in Europe





# PRODUCT AND BUSINESS MODEL



**Novel immunosuppression  
via a new biological entity**



**Topical application using a  
nanotransport system**



**Easy administration by use of  
a special dosage form**



**Immunogenicity reduction  
after transplantation**

**Around 1.500 m<sup>2</sup> of allogeneic skin is  
transplanted in Europe annually**

**Approx. 2 L drug product is needed per  
m<sup>2</sup> body surface**

**Estimated price for drug product is  
4000 € per L**

**For 50 % of European patients:  
Approx. 6 M€ revenue annually**

**With 150 k severe burn cases  
worldwide: 1,2 B€ annual revenue**



# COOPERATIONS



Technische  
Universität  
Braunschweig



Leibniz  
Universität  
Hannover



Physikalisch-Technische Bundesanstalt  
National Metrology Institute



Medizinische Hochschule Hannover  
Klinik für Plastische, Ästhetische,  
Hand- und Wiederherstellungschirurgie



VHV STIFTUNG/



BioIntelligence



klinikum  
leverkusen




Marien  
Hospital  
Witten



# TRACTION

## RESEARCH:

Green dots: immunogenic receptors



research | without treatment | after treatment

## INTELLECTUAL PROPERTY:

- First patent application in preparation
- Further patents in planning

## FUNDING:

- 250k for research
- 150k for startup incubation

VHV STIFTUNG /

 BioIntelligence

● ...

● ...



# TRACTION

## AWARDS:

Breast Cancer Research Junior Award 2022 (for platform technology)



## COOPERATION COMMITMENTS FROM CLINICS:






# MARKET ACCESS AND SALES STRATEGY

## COSTS FOR TREATING COMPLEX WOUNDS

Dressings and materials  
15%

Nurse time  
35%

Hospitalisation  
50%



Lower hospitalisation time

=

significant cost reduction for clinics

- Addressing the market for chronic wounds
- Cooperation with military organisations



# MARKET ACCESS AND SALES STRATEGY

## DISTRIBUTION TO CLINICIANS IN BURN CLINICS

Central facilities in Germany, Europa and North America

## MARKETING

via societies (e.g. European Burn Association), conferences and cooperation partners

## DISTRIBUTION PARTNERSHIPS







for international markets (e.g. Asia, South America)





# COMPETITION

\* = IIb/III degree burns with more than 25 % affected body surface area

	 <b>InCapSolution</b> treatment concept	Autologous skin grafts	Commercial skin substitutes	Skin allograft + immunosuppressants
Application for minor burns				
Applications for severe burn injuries*				
Sufficient barrier function				
Low treatment costs				
No graft rejection				



# ROADMAP

	2023	2024	2025	2026	2027	2028	2029	2030
Development phase								
Preclinic								
GMP-Production								
Healing trials								
Approval phase								
Pharm. quality								
Clinical studies								
Revenue phase								
Capital requirement								

# OUR MARKET



35%

## AMERICA

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

30%

## EUROPE

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

15%


## AFRICA

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

20%

## ASIA

Lorem ipsum dolor sit amet, consectetur adipiscing elit.



# TREND

## PEOPLE


Lorem ipsum dolor sit amet, consectetur adipiscing elit.

## SALES

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

## MARKET

Lorem ipsum dolor sit amet, consectetur adipiscing elit.



458K

People use this product

\$752,000

Total revenue in 2022

86%

Market share in global

# OUR STRATEGY

## Goal

### Key Activity 1

Lorem ipsum dolor sit amet,  
consectetur adipiscing elit.

### Action 1

Lorem ipsum dolor sit  
amet, consectetur  
adipiscing elit.

### Action 2

Lorem ipsum dolor sit  
amet, consectetur  
adipiscing elit.

### Key Activity 2

Lorem ipsum dolor sit amet,  
consectetur adipiscing elit.

### Action 1

Lorem ipsum dolor sit  
amet, consectetur  
adipiscing elit.

### Action2



Lorem ipsum dolor sit  
amet, consectetur  
adipiscing elit.



S

Lorem ipsum dolor sit amet,  
consectetur adipiscing elit,  
sed do eiusmod tempor  
incididunt ut labore et dolore  
magna aliqua.

Lorem ipsum dolor sit amet,  
consectetur adipiscing elit,  
sed do eiusmod tempor  
incididunt ut labore et dolore  
magna aliqua.



O



W

Lorem ipsum dolor sit amet,  
consectetur adipiscing elit,  
sed do eiusmod tempor  
incididunt ut labore et dolore  
magna aliqua.

Lorem ipsum dolor sit amet,  
consectetur adipiscing elit,  
sed do eiusmod tempor  
incididunt ut labore et dolore  
magna aliqua.



T



# THANK YOU

Have any question?

+123-456-7890

hello@incapsolution.com

www.incapsolution.com